Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

No drug has hit the market running like Gilead Sciences'  (NASDAQ: GILD  ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval first in the U.S. Some on Wall Street believe that Sovaldi could earn Gilead north of $8 billion in its first full year on the market alone, an astronomical sum that has blown out hype over this big biotech company's new star drug.

Yet investors have turned on Gilead recently, with much of the criticism coming over Sovaldi's hefty price tag. Enter its competitors in the oral hep C race, with big pharma's Merck (NYSE: MRK  ) looking to take its own bite out of this lucrative opportunity and aiming to knock Gilead and Sovaldi down a peg. Merck's combination hep C therapy of drugs MK-5172 and MK-8742 scored a 98% cure rate in a recent mid-stage trial, and the company's hoping for a victory in its currently underway phase 3 trial for the treatment as well.

Can Merck emerge as an under-the-radar contender to dominate the oral hepatitis C market and compete with Gilead for the billions of dollars at play? In the video below, Motley Fool contributor Dan Carroll takes you through what Merck's facing in its oral hep C combination therapy and whether you can believe in this stock as this hotly contested race heats up.

Why you need to get in on the next wave of health-care innovation
Don't be left behind on a seismic new shift in health-care innovation. The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 18, 2014, at 12:11 PM, Nala wrote:

    Same old, same old news.Gilead is the "Best of Breed", FDA approved, vetted and already proven!

    Try reporting Breaking News vs. old broken news over and over again, talking about the wannabees.

  • Report this Comment On April 21, 2014, at 10:48 AM, mathprof wrote:

    If there was true competition on price then these guys would be cutting each other's prices down to

    where those who are ill would not be priced out of care. It is one thing to recover the cost of R&D and another to charge what the market will bear.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2917075, ~/Articles/ArticleHandler.aspx, 8/31/2014 6:38:22 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement